| 陆莎 祖超 冯征 王艳 卢强 陈召 张天翼 李小飞.71 例Ⅲ-N2 期非小细胞肺癌综合治疗病例的生存分析[J].现代生物医学进展英文版,2015,15(29):5678-5681. |
| 71 例Ⅲ-N2 期非小细胞肺癌综合治疗病例的生存分析 |
| Survival Analysis of III-N2 Non-Small-Cell Lung Cancer in 71 Patients |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 综合疗法 生存分析 |
| 英文关键词: NSCLC Stage III-N2 Combined therapy |
| 基金项目:国家自然科学基金项目(81172224) |
|
| Hits: 950 |
| Download times: 0 |
| 中文摘要: |
| 目的：对71 例Ⅲ-N2 期非小细胞肺癌综合治疗的病例进行生存分析。方法：我院2007 年3 月至2014 年3 月诊断为Ⅲ-N2
期的非小细胞肺癌患者71 例，所有患者均接受手术、诱导或辅助化疗及术后放疗。采用Kaplan-Meier 法对以上患者的总生存期
(overall survival, OS)和无病生存期(disease free survival, DFS)进行分析。结果：71 例患者的中位生存期为32 个月，1 年、3 年和5 年
生存率分别为84.5%、49.6%和35.5%；1 年、3 年和5 年无病生存率分别为70.4%、41.8%和27.4%；9 例患者(12.6%)出现局部复发；
鳞状细胞癌患者的中位生存期为43 个月，而腺癌患者的中位生存期为21 个月。鳞癌患者1 年、3 年、5 年的OS 和DFS 分别为
85%、60%、42.5%和80.0%、55.0%、34.2%；腺癌患者1 年、3 年、5 年的OS 和DFS 分别为77.1%、42.0%、36.0%和60.0%、28.6%、
28.6%，两组OS 和DFS均无显著性差异。结论：不同细胞类型非小细胞肺癌综合治疗生存期存在差异 |
| 英文摘要: |
| Objective:To study the impact of trimodal therapy for stage III-N2 NSCLC a single centre retrospective evaluation focusing
on survival and therapy-related toxicity was performed.Methods:71 patients diagnosed between March 2007 and August 2014
with pathologically confirmed stage III-N2 non-small-cell lung cancer at the University Clinic of Heidelberg were retrospectively analyzed.
All patients were treated within trimodal therapy strategies including surgery, induction or adjuvant chemotherapy and postoperative
radiotherapy. Overall survival (OS) and disease free survival (DFS) rates were calculated using the Kaplan-Meier method.Results:Median survival was 32 months. 1-, 3- and 5-year overall survival (OS) rates were 84.5%, 49.6% and 35.5% respectively. Disease free
survival rates at 1, 3 and 5 years were 70.4%, 41.8%and 27.4%respectively. 9 patients (12.6%) were diagnosed with a local recurrence.
Multivariate analysis did not reveal any independent prognostic factors for OS, but indicated a trend for pT stage and type of surgery.Conclusion:Our descriptive data indicate that trimodal therapy represents an effective and safe treatment approach for patients with
stage III-N2 non-small-cell lung cancer. Differences survival was found in different kinds of NSCLC with comprehensive treatment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
